Results from in vitro, ectopic, overexpression studies of individual p38 subtypes in cardiomyocytes are at odds with cardiomyocyte-targeted in vivo genetic inhibition studies, yet pharmacologic p38α inhibition appears effective at reducing cardiac hypertrophy. Here, MAPK14 is linked to cardiac hypertrophy.